...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Effectively introducing a new meningococcal A conjugate vaccine in Africa: The Burkina Faso experience
【24h】

Effectively introducing a new meningococcal A conjugate vaccine in Africa: The Burkina Faso experience

机译：在非洲有效引进新的脑膜炎球菌A结合疫苗：布基纳法索的经验

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A new Group A meningococcal (Men A) conjugate vaccine, MenAfriVac (TM), was prequalified by the World Health Organization (WHO) in June 2010. Because Burkina Faso has repeatedly suffered meningitis epidemics due to Group A Neisseria meningitidis special efforts were made to conduct a country-wide campaign with the new vaccine in late 2010 and before the onset of the next epidemic meningococcal disease season beginning in January 2011. In the ensuing five months (July-November 2010) the following challenges were successfully managed: (1) doing a large safety study and registering the new vaccine in Burkina Faso; (2) developing a comprehensive communication plan; (3) strengthening the surveillance system with particular attention to improving the capacity for real-time polymerase chain reaction (PCR) testing of spinal fluid specimens; (4) improving cold chain capacity and waste disposal; (5) developing and funding a sound campaign strategy; and (6) ensuring effective collaboration across all partners. Each of these issues required specific strategies that were managed through a WHO-led consortium that included all major partners (Ministry of Health/Burkina Faso, Serum Institute of India Ltd., UNICEF, Global Alliance for Vaccines and Immunization, Meningitis Vaccine Project, CDC/Atlanta, and the Norwegian Institute of Public Health/Oslo). Biweekly teleconferences that were led by WHO ensured that problems were identified in a timely fashion. The new meningococcal A conjugate vaccine was introduced on December 6, 2010, in a national ceremony led by His Excellency Blaise Compaore, the President of Burkina Faso. The ensuing 10-day national campaign was hugely successful, and over 11.4 million Burkinabes between the ages of 1 and 29 years (100% of target population) were vaccinated. African national immunization programs are capable of achieving very high coverage for a vaccine desired by the public, introduced in a well-organized campaign, and supported at the highest political level. The Burkina Faso success augurs well for further rollout of the Men A conjugate vaccine in meningitis belt countries. (C) 2012 Elsevier Ltd. All rights reserved.
机译：一种新的A组脑膜炎球菌（Men A）结合疫苗MenAfriVac（TM）已于2010年6月获得世界卫生组织（WHO）的资格预审。由于布基纳法索因A组脑膜炎奈瑟菌而反复遭受脑膜炎的流行，因此我们做出了特别努力在2010年底和下一个从2011年1月开始的下一流行性脑膜炎球菌季节开始之前，使用新疫苗在全国范围内开展运动。在随后的五个月（2010年7月至11月）中，成功应对了以下挑战：（1）在布基纳法索进行大规模的安全研究并注册新疫苗; （2）制定全面的沟通计划; （3）加强监视系统，特别注意提高脊液标本的实时聚合酶链反应（PCR）检测能力; （4）提高冷链能力和废物处置能力; （5）制定并资助合理的竞选策略; （6）确保所有合作伙伴之间的有效合作。这些问题中的每一个都需要由包括所有主要合作伙伴（卫生部/布基纳法索，印度血清研究所有限公司，联合国儿童基金会，全球疫苗和免疫联盟，脑膜炎疫苗项目，疾病预防控制中心）在内的世卫组织牵头的财团管理的具体战略。 /亚特兰大和挪威公共卫生学院/奥斯陆）。由世卫组织主持的每两周一次的电话会议确保及时发现问题。新的脑膜炎球菌A结合疫苗于2010年12月6日在布基纳法索总统布莱斯·孔波雷阁下阁下主持的国家级仪式上推出。随后进行的为期10天的全国运动取得了巨大成功，为1至29岁（目标人口的100％）的1140万布基纳法索人接种了疫苗。非洲国家免疫计划能够为公众所期望的疫苗提供非常高的覆盖率，在组织良好的运动中引入并得到最高政治级别的支持。布基纳法索的成功预示着在脑膜炎带国家进一步推广Men A结合疫苗的成功。 （C）2012 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号